SH-SY5Y Human Neuroblastoma Cell Line: in Vitro Cell Model of Dopaminergic Neurons in Parkinson's Disease
Overview
Authors
Affiliations
Objective: To evaluate the human neuroblastoma SH-SY5Y cell line as an in vitro model of dopaminergic (DAergic) neurons for Parkinson's disease (PD) research and to determine the effect of differentiation on this cell model.
Data Sources: The data of this review were selected from the original reports and reviews related to SH-SY5Y cells published in Chinese and foreign journals (Pubmed 1973 to 2009).
Study Selection: After searching the literature, 60 articles were selected to address this review.
Results: The SH-SY5Y cell line has become a popular cell model for PD research because this cell line posses many characteristics of DAergic neurons. For example, these cells express tyrosine hydroxylase and dopamine-beta-hydroxylase, as well as the dopamine transporter. Moreover, this cell line can be differentiated into a functionally mature neuronal phenotype in the presence of various agents. Upon differentiation, SH-SY5Y cells stop proliferating and a constant cell number is subsequently maintained. However, different differentiating agents induce different neuronal phenotypes and biochemical changes. For example, retinoic acid induces differentiation toward a cholinergic neuronal phenotype and increases the susceptibility of SH-SY5Y cells to neurotoxins and neuroprotective agents, whereas treatment with retinoic acid followed by phorbol ester 12-O-tetradecanoylphorbol-13-acetate results in a DAergic neuronal phenotype and decreases the susceptibility of cells to neurotoxins and neuroprotective agents. Some differentiating agents also alter kinetics of 1-methyl-4-phenyl-pyridinium (MPP(+)) uptake, making SH-SY5Y cells more similar to primary mesencephalic neurons.
Conclusions: Differentiated and undifferentiated SH-SY5Y cells have been widely used as a cell model of DAergic neurons for PD research. Some differentiating agents afford SH-SY5Y cells with more potential for studying neurotoxicity and neuroprotection and are thus more relevant to experimental PD research.
Moradi Vastegani Z, Ghaedi-Heidari R, Oroujalian A, Peymani M, Ghaedi K Metab Brain Dis. 2025; 40(3):141.
PMID: 40067516 DOI: 10.1007/s11011-025-01568-z.
Lazzeri G, Lenzi P, Signorini G, Raffaelli S, Giammattei E, Natale G Int J Mol Sci. 2025; 26(4).
PMID: 40004155 PMC: 11855701. DOI: 10.3390/ijms26041691.
Duarte P, Sanchez-Porro F, Crisman E, Cores A, Jimenez I, Cuadrado A J Med Chem. 2025; 68(3):3495-3517.
PMID: 39818855 PMC: 11881042. DOI: 10.1021/acs.jmedchem.4c02659.
Qin G, Song R, Sun J, Chen B, Liu Z, Han L 3 Biotech. 2024; 15(1):14.
PMID: 39703418 PMC: 11652558. DOI: 10.1007/s13205-024-04181-6.
Rivera-Maya O, Ortiz-Robles C, Palacios-Valladares J, Calderon-Aranda E Neurochem Res. 2024; 50(1):35.
PMID: 39601897 PMC: 11602804. DOI: 10.1007/s11064-024-04293-8.